Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol buying out Axion stake in Oncology Therapeutics Network joint venture.

Executive Summary

BRISTOL TO BUY OUT ONCOLOGY THERAPEUTICS NETWORK JOINT VENTURE from co-owner Axion, a San Bruno, Calif.-based oncology specialty firm, BMS announced Aug. 5. Bristol-Myers Squibb bought a 50% interest in Oncology Therapeutics Network in 1993. Axion founded its physician-office oncology product distribution business in 1990.

You may also be interested in...



Bristol Exiting Oncology Distribution Business Ahead Of Part B Pinch

Bristol-Myers Squibb has signed an agreement to sell its Oncology Therapeutics Network unit prior to the 2005 reimbursement changes for chemotherapy drugs under the Medicare Rx law

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel